Xenon Pharmaceuticals Inc (XENE)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Xenon Pharmaceuticals Inc chart...

About the Company

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.

$0M

Total Revenue

236

Employees

$3B

Market Capitalization

-15.86

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $XENE News

Xenon Pharmaceuticals Inc XENE

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Xenon Pharmaceuticals files patent for immediate release tablet for treatment of epilepsy

6d ago, source: Pharmaceutical Technology

Discover Xenon Pharmaceuticals' patent for Compound A, a breakthrough treatment for diseases linked to NaV1.6 activity like epilepsy. Learn about the innovative tablet formulation and granular options ...

Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript

28d ago, source: Seeking Alpha

I would like to welcome you to the Q4 2023 Xenon Pharmaceuticals, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks ...

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

16d ago, source: Business Insider

VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will ...

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

28d ago, source: Business Insider

About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative ...

Xenon Pharmaceuticals: Q4 Earnings Snapshot

29d ago, source: Houston Chronicle

BURNABY, British Columbia (AP) — BURNABY, British Columbia (AP) — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $44.7 million in its fourth quarter. The Burnaby, British ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript

27d ago, source: Yahoo Finance

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.64, expectations were $-0.76.

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

16d ago, source: Stockhouse

The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to ...

Xenon Pharmaceuticals Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Xenon Pharmaceuticals Inc

9d ago, source: U.S. News & World Report

Some funds make more sense to hold in a Roth IRA due to higher income generation, greater turnover or the potential for stronger long-term growth.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...